Q - Adaptive Biotechnologies

For the period ended Jun 30, 2025. Filed Aug 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 5, 2025

ADPT$29.36-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional · Accumulated Other · Accumulated · Noncontrolling · Total
	Shares	Amount	Paid-In Capital	Comprehensive (Loss) Gain	Deficit	Interest	Shareholders’ Equity
Balance at March 31, 2024	147,368,324	$14	$1,466,844	$(106)	$(1,191,839)	$(147)	$274,766
Issuance of common stock for cash upon exercise of stock options	15,000	—	30	—	—	—	30
Vesting of restricted stock units, net	78,877	—	—	—	—	—	—
Share-based compensation expense	—	—	12,958	—	—	—	12,958
Other comprehensive loss	—	—	—	(76)	—	—	(76)
Net loss	—	—	—	—	(46,222)	(26)	(46,248)
Balance at June 30, 2024	147,462,201	$14	$1,479,832	$(182)	$(1,238,061)	$(173)	$241,430
Balance at March 31, 2025	151,916,722	$15	$1,523,950	$134	$(1,333,676)	$(202)	$190,221
Issuance of common stock for cash upon exercise of stock options	238,211	—	1,610	—	—	—	1,610
Vesting of restricted stock units	79,839	—	—	—	—	—	—
Share-based compensation expense	—	—	13,359	—	—	—	13,359
Other comprehensive loss	—	—	—	(61)	—	—	(61)
Net (loss) income	—	—	—	—	(25,614)	21	(25,593)
Balance at June 30, 2025	152,234,772	$15	$1,538,919	$73	$(1,359,290)	$(181)	$179,536

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.